Respirerx Pharmaceuticals Stock Performance
| RSPI Stock | USD 0 0.00 0.00% |
RespireRx Pharmaceuticals holds a performance score of 9 on a scale of zero to a hundred. The company holds a Beta of 0.29, which implies not very significant fluctuations relative to the market. As returns on the market increase, RespireRx Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding RespireRx Pharmaceuticals is expected to be smaller as well. Use RespireRx Pharmaceuticals maximum drawdown and rate of daily change , to analyze future returns on RespireRx Pharmaceuticals.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in RespireRx Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, RespireRx Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
RespireRx |
RespireRx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.11 in RespireRx Pharmaceuticals on October 14, 2025 and sell it today you would earn a total of 0.07 from holding RespireRx Pharmaceuticals or generate 63.64% return on investment over 90 days. RespireRx Pharmaceuticals is currently generating 1.3709% in daily expected returns and assumes 11.5833% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than RespireRx, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RespireRx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RespireRx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as RespireRx Pharmaceuticals, and traders can use it to determine the average amount a RespireRx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1183
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | RSPI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average RespireRx Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RespireRx Pharmaceuticals by adding it to a well-diversified portfolio.
RespireRx Pharmaceuticals Fundamentals Growth
RespireRx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of RespireRx Pharmaceuticals, and RespireRx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RespireRx Pink Sheet performance.
| Return On Asset | -8.34 | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 119.59 M | |||
| Price To Earning | (0.25) X | |||
| Price To Sales | 1,051 X | |||
| EBITDA | (2.42 M) | |||
| Cash And Equivalents | 21 | |||
| Total Debt | 2.42 M | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (956.17 K) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 208.74 K | |||
| Retained Earnings | (156.09 M) | |||
| Current Asset | 157 K | |||
| Current Liabilities | 5.05 M | |||
About RespireRx Pharmaceuticals Performance
By evaluating RespireRx Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into RespireRx Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if RespireRx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if RespireRx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey. Respirerx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about RespireRx Pharmaceuticals performance evaluation
Checking the ongoing alerts about RespireRx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for RespireRx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RespireRx Pharmaceuticals is way too risky over 90 days horizon | |
| RespireRx Pharmaceuticals has some characteristics of a very speculative penny stock | |
| RespireRx Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.14 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RespireRx Pharmaceuticals currently holds about 21 in cash with (956.17 K) of positive cash flow from operations. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RespireRx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RespireRx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining RespireRx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RespireRx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RespireRx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RespireRx Pharmaceuticals' pink sheet. These opinions can provide insight into RespireRx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for RespireRx Pink Sheet analysis
When running RespireRx Pharmaceuticals' price analysis, check to measure RespireRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RespireRx Pharmaceuticals is operating at the current time. Most of RespireRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of RespireRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RespireRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of RespireRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |